Hudson Bay Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Hudson Bay Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-20,000	Closed	-$143K	–	1411
2025 Q3	$143K	Sell	20,000 -85,000	-81%	-$4.43M	﹤0.01%	1043
2025 Q2	$4.96M	Buy	105,000 +25,000	+31%	+$1.02M	0.02%	548
2025 Q1	$3.13M	Buy	80,000 +72,500	+967%	+$3.12M	0.01%	717
2024 Q4	$406K	Buy	+7,500	New	+$383K	﹤0.01%	816
2024 Q3	–	Sell	-15,000	Closed	-$660K	–	977
2024 Q2	$660K	Buy	+15,000	New	+$635K	﹤0.01%	630
2024 Q1	–	Sell	-15,000	Closed	-$906K	–	828
2023 Q4	$906K	Buy	+15,000	New	+$773K	0.01%	528
2023 Q3	–	Sell	-60,000	Closed	-$3.06M	–	893
2023 Q2	$3.06M	Buy	+60,000	New	+$1.61M	0.02%	420

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Hudson Bay Capital Management's MLTX Position: Q4 2025 in Review

Hudson Bay Capital Management sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2025, closing a stake of 20,000 shares — an estimated $143K sold.

Hudson Bay Capital Management first reported a position in MLTX in Q2 2023 and held it in 7 quarters. The position peaked at $4.96M in Q2 2025. 130 funds tracked by Wall St. Rank hold MLTX as of Q4 2025.

Hudson Bay Capital Management reported no remaining MoonLake Immunotherapeutics position as of Q4 2025 after selling out during the quarter.
Hudson Bay Capital Management sold 20,000 MoonLake Immunotherapeutics shares in Q4 2025, an estimated $143K.
Hudson Bay Capital Management first reported a position in MoonLake Immunotherapeutics in Q2 2023 and held it in 7 quarters.
Hudson Bay Capital Management's MoonLake Immunotherapeutics position peaked at $4.96M in Q2 2025.
130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2025.

Based on Hudson Bay Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.